Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) is characterized by its well-defined clinical profile. Limbic encephalitis is increasingly recognized as a possible etiology of adult-onset MTLE-HS, and neuronal autoantibodies have been detected in patients even without previous signs of encephalitis. The aim of this study is to analyze the frequency of specific autoantibodies in patients with MTLE-HS. A case-control study was carried out with 100 patients with MTLE-HS and 50 healthy controls. Sera samples from subjects were tested by indirect immunofluorescence assay for detection of anti-N-methyl-Daspartate receptor (NMDA-R), anti-contactin-associated protein-like 2 (CASPR2), anti-leucine-rich glioma inactivated 1 (LGI1), anti-gamma aminobutyric acid B receptor (GABA-B-R), anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 1 and 2 receptors (AMPA-1-R and AMPA-2-R), and enzyme-linked immunosorbent assay for detection of anti-glutamic acid decarboxylase 65 (GAD65). Mean age of patients and controls was 41.2 vs 42 years, and 55% vs 56% were female. Mean duration of epilepsy was 27.2 years. No neuronal autoantibodies were found in either group, except for anti-GAD65 in 3 patients and 2
autoantibodies directed to neuronal proteins have been detected in patients with epilepsy without signs of previous encephalitis, 3 indicating the possibility of immunotherapyresponsive disorders and respective treatment. A recent study by Vanli-Yavuz et al 4 found a 22.5% prevalence of neuronal autoantibodies in patients with MTLE-HS. To investigate the external validation of their findings, the aim of the present study was to analyze the frequency of neuronal autoantibodies in patients with MTLE-HS from a different immunogenetic background.
| METHODS
A case-control study was carried out with 100 consecutive patients who fulfilled clinical, interictal scalp electroencephalography (EEG), and 1.5 Tesla magnetic resonance imaging (MRI) criteria for MTLE-HS (as described by Wieser et al 2 ) . No temporal mesial other than HS or extratemporal lesions was visible on MRI, and there were no generalized epileptiform discharges on EEG. Patients were followed for at least 1 year by 2 board-certified clinical neurophysiologists/epileptologists (KL, RW) in a tertiary referral hospital (catchment area of 6 million people). Fifty age-and gender-matched controls, without neurologic, psychiatric, or autoimmune diseases were included.
Clinical and demographic data were obtained: precipitating factors, age at seizure onset, duration of epilepsy, frequency of seizures and type of seizures (according to Fisher et al, 2017 5 ), antiepileptic medications, and past history of autoimmune or other diseases. None of the patients had signs or symptoms suggesting active limbic encephalitis. Serum of individuals was collected and stored at −80°C for further analysis. The main neuronal autoantibodies associated with autoimmune encephalitis were tested. Anti-Nmethyl-D-aspartate receptor (NMDA-R), anti-contactin-associated protein-like 2 (CASPR2), anti-leucine-rich glioma inactivated 1 (LGI1), anti-gamma aminobutyric acid B receptor (GABA-B-R), anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 1 and 2 receptors (AMPA-1-R and AMPA-2-R) were tested using a commercial indirect immunofluorescence (IIF) assay and anti-glutamic acid decarboxylase 65 (GAD65) by enzyme-linked immunosorbent assay (ELISA) both from Euroimmun-AG (Lüebeck, Germany). Serum was tested at 1:10 dilution for IIF and undiluted for ELISA. All IIF reactions were read independently by 2 trained researchers (AWNJ, MS), in blinded conditions for both cases and controls. A third party, a technical personnel from Euroimmun (TC), read controversial IIF results and agreement was reached. The defined cutoff for negative anti-GAD was <10 IU/mL. High positive values were considered >1000 IU/mL.
To minimize the possibility of a false-negative result, in addition to the Euroimmun assay standardized positive control, we also tested serum of one patient who fulfilled Graus' clinical criteria for autoimmune encephalitis 6 for these same autoantibodies. All procedures were in accordance with the code of Ethics of World Medical Association and Uniform Requirements for Manuscripts Submitted to Biomedical Journals. The study was started after a local ethics committee's approval. All subjects signed an informed consent form and voluntarily agreed to participate in this study.
The sample size was estimated based on a previous study, which showed a prevalence of 22.5% of neuronal autoantibodies in patients with MTLE-HS. 4 After Bonferroni correction for multiple comparisons (7 different autoantibodies tested) "P" level was adjusted for 0.007 and power to find a prevalence of 15% of autoantibodies in our sample (100 patients, 50 controls) was 80%. Continuous variables were expressed as mean ± standard deviation (SD), whereas categorical variables were expressed as percentages. Differences in distribution of demographic and clinical variables between patients with and without autoantibody positivity were determined by chi-square test, Fisher's exact test, Student t test, and Pearson's correlation. In this analysis no correction was applied for multiple comparisons and P<0.05 was considered statistically significant.
| RESULTS
Patients' mean age was 41.2 ±11.9 years (range 18-67) and of controls, was 42 ±13.1 years (range 19-72); 55% of patients and 56% of controls were female.
Forty-three percent of patients had precipitating events: 25% febrile seizures, 7% central nervous system infection/ inflammation, 5% cerebral hypoxia, 4% head trauma, and 2% other events-one patient had neonatal hypoglycemia and one had a history of fever and left hemiplegia. One patient had both febrile seizures and cerebral hypoxia. Mean age at event was 21.7 ±19.5 months.
Regular seizures began at an average age of 14 years and mean duration of epilepsy was 27.2 ±13.4 years (range 1-56). Only 4 patients (4%) had short disease duration (≤6 years).
Current seizure type was as follows: no seizures 1%, focal-onset nonaware 93%, focal-onset aware 69%, focal to bilateral tonic-clonic 46%. The mean frequency of focal seizures was 6.38/month and focal to bilateral tonic-clonic seizures was 0.74/month.
Patients were on a 2.7 mean number of antiepileptic drugs, and the most commonly used were carbamazepine 72%, phenobarbital 37%, clobazam 31%, and valproate 16%. Seventy percent met the criteria for drug-resistant epilepsy according to Kwan et al, 2010. 7 Four patients had a history of autoimmune disease (2 multiple sclerosis, one systemic sclerosis, and one ulcerative colitis).
Forty-six percent had left, 40% right, and 14% bilateral hippocampal sclerosis on MRI. Thirteen percent had nonspecific white matter lesions with nonpredominant location. Forty-five percent had bursts of focal slow waves, and 59% had interictal paroxysmal epileptiform discharges on EEG.
Anti-NMDA-R, anti-CASPR2, anti-LGI1, anti-GABA-B-R, anti-AMPA-1-R, and anti-AMPA-2-R were not found in either group. The patient who fulfilled Graus' clinical criteria of autoimmune encephalitis, 6 who was tested as a real-life positive control, had serum antibodies against NMDA-R at a titer of 1:100. Elevated anti-GAD (>10 IU/mL) was found in 3 patients and 2 controls (P = 0.75). Two MTLE patients had high concentrations of 1830.3 IU/mL and 1849.8 IU/ mL; one had 249.7 IU/mL. None of the controls was high positive for GAD antibodies (P = 0.31). Two controls had elevated concentrations at 11.2 IU/mL and 222 IU/mL. There was no difference between anti-GAD positive and negative patients, regarding clinical-demographic characteristics, except for the presence of autoimmune diseases (Table 1) .
| DISCUSSION
There are few studies on neuronal autoantibodies in a homogeneous group specifically with MTLE-HS. To the best of our knowledge, there are only 3 studies in the field other than ours: two from Turkey 4, 8 and one from Brazil (presented in a poster session in a regional neurology congress).
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Our study challenges the published study from VanliYavuz et al, 4 which showed a 22.5% prevalence of neuronal autoantibodies (anti-CASPR2, anti-uncharacterized VGKC-complex antigens, anti-GLY-R, anti-NMDA-R, and On the other hand, anti-GAD was reported in 15/253 patients with epilepsy (7 with high titers) and in 3/20 controls (all low-positives), and all positive patients had TLE, not extra-TLE or idiopathic generalized epilepsy. 12 Vanli-Yavuz et al 4 reported 20% of coexisting autoimmune disease in the seropositive group, but it was not statistically different from seronegative group. 4 In our study, other autoimmune diseases were observed more frequently in the anti-GAD-positive group (P = 0.008). Our population is very similar to the patients of VanliYavuz et al 4 with MTLE-HS regarding mean age (41.2 vs 38 years), gender (55 vs 58.5% female), and mean duration of epilepsy (27.2 vs 24.7 years), but the frequency of febrile seizures is lower in our population (25% vs 64%). Although this may be explained by underreporting, we may hypothesize that some mechanisms of the initial event may induce the appearance of neuronal autoantibodies and clinical phenomena will only appear many years after that precipitating event, like other chronic autoimmune diseases. Compared to other causative events, febrile seizures can be one of the most immunogenic ones: neurotropic viral infections have a role in febrile seizures 13 and they can lead to presentation of self-neuronal antigens to immune system, inducing the formation of autoantibodies. IL-1β (evidence of active brain inflammation) was demonstrated in animal models of febrile seizures. 14 This may be a proper scenario to antigen presentation and autoimmune response. Therefore, high frequency of febrile seizures as a precipitating event may be an explanation of the higher frequency of neuronal autoantibodies in the Turkish population. Our patients were not tested for anti-GLYR and uncharacterized VGKC-complex antigens, which were detected in 4.5% and 3.6%, respectively, of patients investigated by Vanli-Yavuz et al. 4 Our findings are limited to serum autoantibodies. However, it has been described that some neuronal autoantibodies show a higher sensitivity in the cerebrospinal fluid. 6 The controversial results might be also explained by genetic and environment differences between the 2 studied populations. Human leukocyte antigen HLA proteins mediate a complex interaction of the immune system with the environment. 15 Differences in the accuracy of the used immune assay also need to be considered. For autoimmune encephalitis the sensitivity of the Euroimmun assay ranges from 82% to 100% and the specificity from 99.3% to 100%, depending on the autoantibodies tested. 19 We did not find any data about the accuracy of the "in-house" assay used by VanliYavuz et al 4 in their Turkish patients. Of interest, in another study with 15 Turkish patients with pathologic proved HS using the Euroimmun assay, Tezer et al 8 didn't find any positive result. In addition, a low prevalence (4.4%) of autoantibodies was described in patients with MTLE-HS without limbic encephalitis (n = 45) from São Paulo 9 tested with the Euroimmun assay. In the same Brazilian study, the additional 2 cases with clinical symptoms of limbic encephalitis were positive for anti-NMDAR, suggesting a high sensitivity of the assay. 9 This is the second largest consecutive series of an MRIconfirmed MTLE-HS patient group, systematically investigated for neuronal autoantibodies in an immunogenetically different population, challenging the recent findings of Vanli-Yavuz et al. 4 In our population, MTLE-HS is infrequently associated with the presence of the mentioned neuronal autoantibodies. These results do not support the external validation for the association between serum autoantibodies and MTLE-HS. Further works using different "in-house" and commercial autoantibody assays tested simultaneously in different populations may help clarify differences in autoantibody frequency observed among MTLE-HS patients. 
T A B L E 1 Clinical-demographic characteristics for anti-GAD positive and negative patients
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